Login to Your Account

Financings Roundup

Tuesday, May 31, 2011
Bavarian Nordic A/S, of Kvistgard, Denmark, reported that it completed an offering of about 12.9 million shares and netted about $124.9 million to support development of its prostate cancer vaccine candidate Prostvac, particularly its pivotal Phase III trial. (See BioWorld Today, April 5, 2011.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription